Trial Search Results
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Albert Koong
Stanford Investigator(s):
Intervention(s):
- Radiation: Stereotactic Body Radiotherapy
- Drug: Gemcitabine
- Other: 4D pancreatic protocol CT scan
- Radiation: FDG PET scan
Phase:
Phase 2
Eligibility
Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension
- Histologically confirmed malignancies of the pancreas
- Unresectable by CT criteria or exploratory laparotomy or laparoscopy
- Patients with metastatic disease may be treated if they are symptomatic from the
primary tumor
- Performance status of 0, 1, or 2
- No chemotherapy two weeks prior or two weeks following radiosurgery
Exclusion Criteria:
- patients who have had prior radiotherapy to upper abdomen
- patients receiving any prior pancreatic cancer therapy
- children, pregnant, and breastfeeding women, and lab personnel are excluded
- uncontrolled intercurrent illnesses
- any concurrent malignancy
Ages Eligible for Study
18 Years - 90 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jeff Kim
6504987703
Not Recruiting